Classifier Predicts Efficacy of Immune Checkpoint Inhibitor Therapy in Renal Cell Carcinoma
Researchers applied a 27-gene classifier proven effective with breast, lung, and bladder cancers to predict efficacy of ICI therapy in patients with RCC.
Renal Cell Carcinoma
Study: Risk Score Should Guide Deferral of Cytoreductive Nephrectomy
Ideal patient selection for a deferred cytoreductive nephrectomy should include an assessment of Memorial Sloan Kettering Cancer Center risk score, according to investigators.
Renal Mass Size Could Help Assess Need for Chest Imaging
Synchronous lung metastasis occurs in less than 1% of patients with renal masses less than 4 cm in diameter, so chest imaging in these cases may be unwarranted, according to investigators.
Guideline Deviation in Kidney Cancer Care More Likely in Women, Black Patients
Compared with men, women had significant 18% lower odds of undertreatment and 27% higher odds of overtreatment of kidney cancer, according to a study.
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Delaying Surgical Intervention Not Likely to Increase Mortality in Patients With Metastatic Renal Cell Carcinoma
Systematic review and meta-analysis assessed the impact of delayed surgical intervention on localized and metastatic renal cell carcinoma.
Understanding Adverse Effects Associated With Immune-Based Combination Therapies for Metastatic Renal Cell Carcinoma
A meta-analysis of phase 3 randomized control trials sought to identify the TRAEs associated with 7 therapeutic regimens for the treatment of mRCC.
Pembrolizumab After RCC Surgery: Potential New Standard of Care
In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.
Two-Drug Regimen Offers Better Health-Related Quality of Life in Advanced Renal Cell Carcinoma
The combination of lenvatinib and pembrolizumab improved health-related quality of life.
Telaglenastat Fails to Improve Outcomes in Previously Treated Metastatic RCC
Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...